Using the AACR Health Disparities Report to Drive Change in Cancer Care

Commentary
Video

The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.

The American Association for Cancer Research (AACR) Health Disparities Report is a powerful tool that can help educate those in the oncology community on health equity issues among patients with cancer, according to Robert A. Winn, MD.

Winn described his experiences with organizing the AACR Health Disparities Reports since the publication of the first in 2020. He stated that he was “happy” to be involved in this effort to help spread awareness of cancer disparities.

Winn, director and Lipman Chair in Oncology at Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, senior associate for Cancer Innovation, and professor of Pulmonary Disease and Critical Cancer Medicine at VCU School of Medicine, also touched on how working with other professional bodies such as the American Cancer of Clinical Oncology (ASCO) may achieve the goal of educating others on heath disparity issues in oncology.

Transcript:

The education part of this is exciting for us. I hope that the AACR Health Disparities Report is just 1 tool to not only get my colleagues but to get people within the community and get those people who are in charge of our resources a little bit more up-to-speed and aware. This report has, on its own, been substantiated. I was part of the first one in 2020, and part of the second one in 2022. I’m happy to be part of [the 2023] one as well and leading the charge of the 2024 report. That’s one element that we hope will be able to help educate people and bring awareness. The other one is just [the] good old-fashioned [strategy of] having our professional bodies, whether they’re AACR, AACI [Association of American Cancer Institutes], American Cancer Society, or ASCO [American Society of Clinical Oncology] all working on one accord, and that is to bring to the attention that cancer is not like it used to be in the 1950s. It is not necessarily a death sentence if you can get to the right place and get the right care at the right time.

Reference

Experts forecast 2024, part 2: achieving cancer health equity. News release. AACR. January 12, 2024. Accessed February 16, 2024. https://shorturl.at/cMQR8

Recent Videos
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.